日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.

一种以吡咯并苯二氮卓类药物为有效载荷的人源化间变性淋巴瘤激酶(ALK)靶向抗体药物偶联物,在表达ALK的癌症中显示出疗效

Guerra Alberto D, Matkar Smita, Acholla Christina, Casey Colleen, Li Grant, Mazzeschi Martina, Patel Khushbu, Krytska Kateryna, Chen Chuan, Balyasny Skye, Kalna Joshua, Kamitsuka Paul, Gerelus Mark, Polkosnik Grace, Groff David, Mukherje Apratim, Adams Cynthia, Witek Gabriela, Hamilton Amber K, Martinez Daniel, Pogoriler Jennifer, Spear Timothy T, Li Yimei, Jung Piotr, Alvarado Diego, Lauriola Mattia, Maris John M, Wolpaw Adam J, Bosse Kristopher R, Dimitrov Dimiter, Mir Mustafa, Jelev Dontcho V, Mossé Yael P

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.

G2/M期激酶的激酶组重编程和MYCN的抑制有助于洛拉替尼在ALK驱动的神经母细胞瘤中发挥更优异的疗效

Matkar Smita, East Michael P, Stuhlmiller Timothy J, Witek Gabriela M, Farrel Alvin, Pastor Steven, Okumu Denis O, Kennedy Anne, Kalna Joshua R, Berko Esther R, Casey Colleen E, Krytska Kateryna, Patel Khushbu, Rokita Jo Lynne, Gerelus Mark, Maris John M, Johnson Gary L, Mossé Yael P